Immunoinformatic multi-epitope vaccine for Gardnerella vaginalis shows stability and strong TLR2/4 binding
Background
Bacterial vaginosis (BV), primarily caused by Gardnerella vaginalis, is a highly prevalent form of vaginal dysbiosis with increasing global health concerns. Current treatments often face challenges like recurrence and antibiotic resistance, highlighting a critical need for preventative strategies. The development of a vaccine could significantly enhance human immunity against BV and mitigate its transmission. This study addresses this gap by leveraging immunoinformatic methodologies to design a multi-epitope vaccine, aiming to stimulate robust immune responses against Gardnerella vaginalis.
Study Design
Researchers employed immunoinformatic methodologies to design a multi-epitope vaccine against Gardnerella vaginalis. B-cell and T-cell epitopes were identified using IEDB and NetCTL servers. Specifically, HTL epitopes were predicted against HLA-DR alleles (including DRB101:01, DRB103:05, and DRB104:04), while CTL epitopes targeted HLA class I supertypes (HLA-A02:01 and HLA-A*01:01). The selected epitopes were fused using GGGS and HEYGAEALERAG linkers, incorporating the MSPSVRHSPSVRH peptide sequence, derived from Mycobacterium tuberculosis heat shock protein 60 (HSP60), as an adjuvant to activate TLR2/4 and enhance dendritic cell maturation. Epitopes were chosen based on antigenicity, allergenicity, and immunological features, with molecular docking used to assess TLR2 and TLR4 interactions.
Results
The computationally designed multi-epitope vaccine construct demonstrated favorable physicochemical and immunological properties. It exhibited a molecular weight of 49924.79 Da and an antigenicity value of 1.37. The vaccine construct showed stability, indicated by an instability score of 32.65, and a projected isoelectric point (pI) of 5.09, suggesting basicity. Its predicted secondary structure comprised 94.57% random coil and 5.43% extended strand. Molecular docking simulations revealed strong interactions with innate immune receptors: > The suggested vaccine demonstrated efficient binding to its TLR2 and TLR4 receptors, yielding maximum Van der Waals energies of (-97.2 +/- 5.9) and (-67.6 +/- 7.3) kcal/mol, respectively. These robust binding affinities suggest the vaccine's potential to effectively activate innate immunity via TLR2 and TLR4 pathways.
Key Findings
- Vaccine construct showed a molecular weight of 49924.79 Da and an antigenicity value of 1.37.
- Instability score of 32.65 indicated stability, with a projected isoelectric point (pI) of 5.09.
- Predicted secondary structure was 94.57% random coil and 5.43% extended strand.
- Demonstrated efficient binding to
TLR2(-97.2 +/- 5.9 kcal/mol) andTLR4(-67.6 +/- 7.3 kcal/mol).
Why It Matters
This computational vaccine design offers a promising blueprint for a novel prophylactic strategy against Bacterial Vaginosis (BV). It highlights the potential of immunoinformatics to accelerate vaccine development, particularly for complex infections like BV where traditional approaches face challenges. The strong predicted binding to TLR2 and TLR4 suggests a robust innate immune activation, crucial for effective pathogen clearance and immune memory. This work provides a solid foundation for future in vitro and in vivo validation, potentially leading to a new tool for reducing BV prevalence and transmission, an area where current interventions are often insufficient and recurrence rates are high.
bacterial vaginosis
gardnerella vaginalis
vaccine
immunoinformatics
tlr2
tlr4